A Phase 3 interventional study of Benralizumab and Placebo to Benralizumab in Non-cystic Fibrosis Bronchiectasis, sponsored by AstraZeneca. Terminated at 48 sites in 16 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2025-07-20.
Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 65 studies in Bronchiectasis with a site in United States — 21 open to participants now, 23 under way, 2 of them phase 3. Bronchiectasis · United States.
Among the 65 studies in Bronchiectasis with a site in United States, this one is the 23rd largest by enrollment of the 52 interventional ones that give a count, is one of 3 that started in 2021, is one of 14 in phase 3, and was the 39th registered.
404 studies on the registry are indexed under Bronchiectasis; 125 are open to participants now.
Browse Bronchiectasis studies →21 of the 65 studies in Bronchiectasis with a site in United States are open now. Recruiting first, the newest first:
Mayo Clinic · Sites in United States
Ages 18+
UCB Biopharma SRL · Sites in United States
Ages 18–80
Indiana University · Sites in United States
Ages 18+
AstraZeneca · Sites in United States, Argentina, Australia and 22 more countries
Ages 12+
GlaxoSmithKline · Sites in United States, Argentina, China and 9 more countries
Ages 18–85
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 93 Bronchiectasis studies recruiting now, 50 (54%) set no upper age limit and 13 (14%) stop at 75 or younger; 12 take children under 18; 26 take healthy volunteers.
This study: 18 Years to 130 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
65 studies; the count open now beside each. This study's row is marked.
First in 1988; this study’s year is marked. 3 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 100 is above the median of 60 across 263 interventional studies indexed under Bronchiectasis.
Median enrollment 78 across the 52 interventional studies, 100 across the 13 observational. Of the 39 that completed or were terminated, 20 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 65 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
AstraZeneca has 6 studies filed under Bronchiectasis — fewer than ten, so there is no comparison to draw.
8 of the studies in Bronchiectasis with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06872892Phase 3Boehringer IngelheimThe AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis | 2027-06-15 |
| NCT05860803Mayo ClinicBreathing Training and Exercise Capacity in Non-CFB | 2026-12-01 |
| NCT07135284Synchrony-Medical, LtdReal Life Evaluation of the LibAirty Airway Clearance System in Adults With Bronchiectasis (RELACS) | 2027-02 |
| NCT05846230Boehringer IngelheimClairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine | 2027-03-31 |
| NCT03839992Gelb, Arthur F., M.D.Detection of Unsuspected Small Airways Obstruction in Cystic Fibrosis | 2027-04-25 |
Add all 8 to your calendar (.ics) → With an account.
Among the 65 studies in Bronchiectasis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicentre, randomised, double-blind, parallel-group, placebo-controlled, phase III study originally designed to test the hypothesis that benralizumab will reduce exacerbation rates compared with placebo on top of standard-of-care therapy in adult patients with non-cystic fibrosis bronchiectasis with eosinophilic inflammation (NCFB+EI).
All patients who complete the double-blind treatment period (28 to 52 weeks depending on the timing of patient randomization and when the revised CSP version 3.0 becomes effective) on investigational product (IP) may be eligible to continue into an open-label extension (OLE) period during which all patients will receive benralizumab.
The revised OLE period is intended to allow patients approximately 32 weeks of treatment with open label benralizumab (24 weeks followed by a FU visit 8 weeks after the last dose of IP for a total of approximately 32 weeks).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Any other clinical condition that is not stable in the opinion of the Investigator and could:
Current , or history of malignancy, except for:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Benralizumab will be administered subcutaneously (SC) using an accessorized prefilled syringe (APFS)
Biological: Benralizumab
Matching placebo solution will be administered subcutaneously (SC) using an accessorized prefilled syringe (APFS)
Biological: Placebo to Benralizumab
Benralizumab active solution in a single accessorized prefilled syringe (APFS) will be administered subcutaneously (SC), 1 mL fill volume
Matching placebo solution in a single accessorized prefilled syringe (APFS) will be administered subcutaneously (SC), 1 mL fill volume
Annualized Bronchiectasis Exacerbations Rate in the Double-blind Period
Annualized Non-Cystic Fibrosis Bronchiectasis (NCFB) exacerbations rate through end of double-blind treatment period.
Time frame: through Double-blind period, at least 28 weeks and up to 52 weeks
Time to First Exacerbation in the Double-blind Treatment Period
Time to first NCFB exacerbation in the double-blind treatment period
Time frame: through Double-blind period, at least 28 weeks and up to 52 weeks
Change From Baseline in QoL-B-RSS Over the Double-blind Period
Change from baseline in Quality of Life-Bronchiectasis-Respiratory Symptoms Scale over the double-blind treatment period. QoL-B-RSS scores range from 0 to 100, with higher scores indicative of better health-related quality of life.
Time frame: through Double-blind period, at least 28 weeks and up to 52 weeks
Change From Baseline in Pre-dose Pre-BD FEV1 Over the Double-blind Treatment Period
Change from baseline in pre-dose pre-bronchodilator (BD) forced expiratory volume in one second (FEV1) over the double-blind treatment period
Time frame: through Double-blind period, at least 28 weeks and up to 52 weeks
Change From Baseline in LCQ Total Score Over the Double-blind Period
Change from baseline in Leicester Cough Questionnaire (LCQ) total score over the double-blind treatment period. LCQ total scores range from 3 to 21. Higher scores indicate better quality of life.
Time frame: through Double-blind period, at least 28 weeks and up to 52 weeks
Change From Baseline in QoL-B Scales (Excluding QoL-B-RSS) Over the Double-blind Period: Physical Functioning Scale
change from baseline in Quality of Life-Bronchiectasis (QoL-B) scales (excluding QoL-B-RSS) over the double-blind treatment period: Physical Functioning Scale. QoL-B Physical Functioning Scale scores range from 0 to 100, with higher scores indicative of better health-related quality of life.
Time frame: through Double-blind period, at least 28 weeks and up to 52 weeks
Change From Baseline in QoL-B Scales (Excluding QoL-B-RSS) Over the Double-blind Period: Role Functioning Scale
Change from baseline in Quality of Life-Bronchiectasis (QoL-B) scales (excluding QoL-B-RSS) over the double-blind treatment period: Role Functioning Scale. QoL-B Role Functioning Scale scores range from 0 to 100, with higher scores indicative of better health-related quality of life.
Time frame: through Double-blind period, at least 28 weeks and up to 52 weeks
Change From Baseline in QoL-B Scales (Excluding QoL-B-RSS) Over the Double-blind Period: Emotional Functioning Scale
Change from baseline in Quality of Life-Bronchiectasis (QoL-B) scales (excluding QoL-B-RSS) over the double-blind treatment period: Emotional Functioning Scale. QoL-B Emotional Functioning Scale scores range from 0 to 100, with higher scores indicative of better health-related quality of life.
Time frame: through Double-blind period, at least 28 weeks and up to 52 weeks
Change From Baseline in QoL-B Scales (Excluding QoL-B-RSS) Over the Double-blind Period: Social Functioning Scale
Change from baseline in Quality of Life-Bronchiectasis (QoL-B) scales (excluding QoL-B-RSS) over the double-blind treatment period: Social Functioning Scale. QoL-B Social Functioning Scale scores range from 0 to 100, with higher scores indicative of better health-related quality of life.
Time frame: through Double-blind period, at least 28 weeks and up to 52 weeks
Change From Baseline in QoL-B Scales (Excluding QoL-B-RSS) Over the Double-blind Period: Vitality Scale
Change from baseline in Quality of Life-Bronchiectasis (QoL-B) scales (excluding QoL-B-RSS) over the double-blind treatment period: Vitality Scale. QoL-B Vitality Scale scores range from 0 to 100, with higher scores indicative of better health-related quality of life.
Time frame: through Double-blind period, at least 28 weeks and up to 52 weeks
Change From Baseline in QoL-B Scales (Excluding QoL-B-RSS) Over the Double-blind Period: Health Perceptions Scale
Change from baseline in Quality of Life-Bronchiectasis (QoL-B) scales (excluding QoL-B-RSS) over the double-blind treatment period: Health Perceptions Scale. QoL-B Health Perceptions Scale scores range from 0 to 100, with higher scores indicative of better health-related quality of life.
Time frame: through Double-blind period, at least 28 weeks and up to 52 weeks
Change From Baseline in QoL-B Scales (Excluding QoL-B-RSS) Over the Double-blind Period: Treatment Burden Scale
Change from baseline in Quality of Life-Bronchiectasis (QoL-B) scales (excluding QoL-B-RSS) over the double-blind treatment period: Treatment Burden Scale. QoL-B Treatment Burden Scale scores range from 0 to 100, with higher scores indicative of better health-related quality of life.
Time frame: through Double-blind period, at least 28 weeks and up to 52 weeks
Change From Baseline in SGRQ Total Score Over the Double-blind Treatment Period
Change from baseline in St. George's Respiratory Questionnaire (SGRQ) total score over the double-blind treatment period. SGRQ total scores range from 0 to 100. 100 represents the worst possible health status and 0 indicates the best possible health status.
Time frame: through Double-blind period, at least 28 weeks and up to 52 weeks
The plan was to randomize 420 eligible patients in a 1:1 ratio to receive either benralizumab or a matching placebo after screening. Patients were stratified at randomization by screening blood eosinophil category, country, and current chronic macrolide use. Due to the decision to stop recruitment early, 100 patients were randomized to receive benralizumab or placebo (20:80 in the low \& high blood eosinophil strata). The revised DB treatment period was at least 28 weeks and up to 52 weeks.
| Milestone | Benralizumab 30 mg | Placebo |
|---|---|---|
| Started | 54 | 45 |
| Treated | 54 | 45 |
| Completed | 42 | 42 |
| Not completed | 12 | 3 |
| Withdrew: Physician decision | 2 | 0 |
| Withdrew: Study terminated by sponsor | 1 | 0 |
| Withdrew: Withdrawal by subject | 7 | 2 |
| Withdrew: Protocol violation | 2 | 0 |
| Withdrew: Subject decision without consent withdrawn | 0 | 1 |
| Milestone | Benralizumab 30 mg | Placebo |
|---|---|---|
| Started | 38 | 40 |
| Completed | 38 | 39 |
| Not completed | 0 | 1 |
| Withdrew: Subject decision without consent withdrawn | 0 | 1 |
Annualized Non-Cystic Fibrosis Bronchiectasis (NCFB) exacerbations rate through end of double-blind treatment period.
| exacerbations per year | Benralizumab 30 mg | Placebo |
|---|---|---|
| Annualized Bronchiectasis Exacerbations Rate in the Double-blind Period | 1.44 (1.05 to 1.97) | 1.27 (0.89 to 1.80) |
Time to first NCFB exacerbation in the double-blind treatment period
| days | Benralizumab 30 mg | Placebo |
|---|---|---|
| Time to First Exacerbation in the Double-blind Treatment Period | 233 (118 to NA) | 316 (141 to NA) |
Change from baseline in Quality of Life-Bronchiectasis-Respiratory Symptoms Scale over the double-blind treatment period. QoL-B-RSS scores range from 0 to 100, with higher scores indicative of better health-related quality of life.
| score on a scale | Benralizumab 30 mg | Placebo |
|---|---|---|
| Week 2 | 6.6 ± 12.57 | 3.1 ± 11.65 |
| Week 4 | 5.8 ± 12.53 | -1.5 ± 12.49 |
| Week 6 | 6.8 ± 14.39 | 0.7 ± 10.94 |
| Week 8 | 6.6 ± 14.17 | 2.1 ± 16.29 |
| Week 10 | 5.3 ± 13.02 | -1.0 ± 14.46 |
| Week 12 | 7.2 ± 11.47 | 0.9 ± 15.44 |
| Week 14 | 8.0 ± 12.28 | 3.7 ± 14.63 |
| Week 16 | 6.2 ± 14.51 | 1.3 ± 15.79 |
| Week 18 | 8.6 ± 14.41 | 2.6 ± 18.60 |
| Week 20 | 8.6 ± 15.41 | 1.4 ± 18.58 |
| Week 22 | 8.4 ± 13.30 | 3.9 ± 20.33 |
| Week 24 | 9.3 ± 17.31 | 4.4 ± 17.70 |
| Week 26 | 7.4 ± 15.07 | 3.8 ± 18.40 |
| Week 28 | 6.5 ± 15.92 | 2.7 ± 21.33 |
| Week 30 | 7.5 ± 14.26 | 1.2 ± 17.32 |
| Week 32 | 12.1 ± 14.37 | 2.4 ± 19.09 |
| Week 34 | 7.6 ± 12.58 | 2.8 ± 18.90 |
| Week 36 | 9.6 ± 17.44 | 3.6 ± 19.31 |
| Week 38 | 8.1 ± 14.96 | 1.3 ± 17.68 |
| Week 40 | 9.6 ± 17.32 | -1.1 ± 18.50 |
| Week 42 | 7.1 ± 14.93 | 3.3 ± 16.25 |
| Week 44 | 7.5 ± 15.00 | 0.8 ± 20.76 |
| Week 46 | 8.6 ± 17.76 | 3.4 ± 18.89 |
| Week 48 | 8.1 ± 16.75 | 3.2 ± 20.52 |
| Week 50 | 9.8 ± 14.63 | 0.1 ± 15.42 |
| Week 52 | 7.3 ± 17.91 | 0.2 ± 18.12 |
Change from baseline in pre-dose pre-bronchodilator (BD) forced expiratory volume in one second (FEV1) over the double-blind treatment period
| L | Benralizumab 30 mg | Placebo |
|---|---|---|
| Week 4 | 0.0139 ± 0.14327 | -0.0477 ± 0.10758 |
| Week 8 | 0.0048 ± 0.15392 | -0.0465 ± 0.15263 |
| Week 16 | -0.0191 ± 0.15964 | -0.0282 ± 0.11452 |
| Week 24 | -0.0378 ± 0.17290 | -0.0595 ± 0.16409 |
| Week 32 | -0.0248 ± 0.16782 | -0.0921 ± 0.17543 |
| Week 40 | -0.0597 ± 0.18924 | -0.1037 ± 0.16808 |
| Week 48 | -0.1236 ± 0.16353 | -0.0849 ± 0.13783 |
| Week 52 | -0.1093 ± 0.13130 | -0.1186 ± 0.14969 |
Change from baseline in Leicester Cough Questionnaire (LCQ) total score over the double-blind treatment period. LCQ total scores range from 3 to 21. Higher scores indicate better quality of life.
| score on a scale | Benralizumab 30 mg | Placebo |
|---|---|---|
| Week 2 | 0.5 ± 2.22 | 0.5 ± 2.13 |
| Week 4 | 0.7 ± 2.35 | 0.0 ± 2.15 |
| Week 6 | 0.8 ± 2.76 | 0.6 ± 2.56 |
| Week 8 | 0.8 ± 3.37 | 0.3 ± 2.85 |
| Week 10 | 1.0 ± 2.77 | 0.1 ± 2.76 |
| Week 12 | 1.0 ± 2.51 | 0.4 ± 3.03 |
| Week 14 | 1.4 ± 2.78 | 0.8 ± 3.16 |
| Week 16 | 0.9 ± 2.61 | 0.5 ± 3.10 |
| Week 18 | 1.0 ± 3.42 | 1.1 ± 3.55 |
| Week 20 | 1.4 ± 3.28 | 0.8 ± 3.39 |
| Week 22 | 0.9 ± 3.32 | 0.8 ± 4.03 |
| Week 24 | 1.0 ± 3.43 | 1.2 ± 3.48 |
| Week 26 | 0.9 ± 3.58 | 1.0 ± 3.54 |
| Week 28 | 0.5 ± 4.31 | 0.9 ± 4.08 |
| Week 30 | 0.7 ± 3.33 | 0.8 ± 4.06 |
| Week 32 | 1.8 ± 3.45 | 0.7 ± 4.14 |
| Week 34 | 0.8 ± 2.43 | 0.8 ± 3.92 |
| Week 36 | 1.2 ± 3.48 | 0.8 ± 3.95 |
| Week 38 | 1.0 ± 3.61 | 0.6 ± 4.24 |
| Week 40 | 1.2 ± 3.93 | 0.2 ± 3.86 |
| Week 42 | 0.6 ± 3.42 | 0.3 ± 4.19 |
| Week 44 | 0.5 ± 3.23 | 0.3 ± 4.02 |
| Week 46 | 0.7 ± 3.68 | 0.6 ± 4.22 |
| Week 48 | 0.3 ± 3.78 | 0.5 ± 4.20 |
| Week 50 | 0.7 ± 3.29 | -0.2 ± 3.41 |
| Week 52 | 0.2 ± 3.94 | -0.1 ± 2.86 |
change from baseline in Quality of Life-Bronchiectasis (QoL-B) scales (excluding QoL-B-RSS) over the double-blind treatment period: Physical Functioning Scale. QoL-B Physical Functioning Scale scores range from 0 to 100, with higher scores indicative of better health-related quality of life.
| score on a scale | Benralizumab 30 mg | Placebo |
|---|---|---|
| Week 2 | 0.5 ± 12.23 | -0.0 ± 16.50 |
| Week 4 | 1.5 ± 17.68 | 0.8 ± 19.39 |
| Week 6 | 4.1 ± 20.81 | 0.2 ± 17.97 |
| Week 8 | 3.3 ± 15.07 | 0.3 ± 20.81 |
| Week 10 | 1.5 ± 19.22 | 1.0 ± 22.06 |
| Week 12 | 3.1 ± 19.54 | 0.5 ± 21.89 |
| Week 14 | 4.4 ± 15.48 | 4.2 ± 22.15 |
| Week 16 | 3.5 ± 18.06 | 3.3 ± 25.17 |
| Week 18 | 4.8 ± 19.15 | 2.2 ± 23.01 |
| Week 20 | 4.5 ± 18.45 | 4.7 ± 25.18 |
| Week 22 | 3.1 ± 19.62 | 2.2 ± 22.96 |
| Week 24 | 5.2 ± 18.21 | 4.7 ± 23.03 |
| Week 26 | 3.6 ± 20.68 | 3.6 ± 24.40 |
| Week 28 | 3.8 ± 24.77 | 4.8 ± 24.39 |
| Week 30 | 2.5 ± 21.33 | 4.8 ± 25.50 |
| Week 32 | 6.7 ± 18.80 | 5.9 ± 24.73 |
| Week 34 | 2.7 ± 19.14 | 3.5 ± 24.90 |
| Week 36 | 0.6 ± 22.76 | 4.7 ± 24.78 |
| Week 38 | 1.9 ± 16.40 | 3.5 ± 23.5 |
| Week 40 | 2.1 ± 23.55 | 4.1 ± 25.01 |
| Week 42 | 1.3 ± 21.13 | 5.5 ± 28.92 |
| Week 44 | 0.6 ± 23.62 | 4.2 ± 24.03 |
| Week 46 | 2.0 ± 22.89 | 7.9 ± 23.42 |
| Week 48 | 0.0 ± 27.89 | 7.6 ± 22.98 |
| Week 50 | 5.3 ± 23.46 | 1.3 ± 21.08 |
| Week 52 | 5.1 ± 23.90 | 2.1 ± 19.25 |
Change from baseline in Quality of Life-Bronchiectasis (QoL-B) scales (excluding QoL-B-RSS) over the double-blind treatment period: Role Functioning Scale. QoL-B Role Functioning Scale scores range from 0 to 100, with higher scores indicative of better health-related quality of life.
| score on a scale | Benralizumab 30 mg | Placebo |
|---|---|---|
| Week 2 | 1.1 ± 13.64 | -1.2 ± 11.11 |
| Week 4 | 2.8 ± 13.00 | -0.3 ± 14.53 |
| Week 6 | 2.7 ± 14.80 | 2.5 ± 12.05 |
| Week 8 | 0.5 ± 16.27 | 0.2 ± 15.02 |
| Week 10 | 1.2 ± 14.09 | 2.7 ± 16.32 |
| Week 12 | 1.7 ± 16.36 | 2.3 ± 16.96 |
| Week 14 | 3.0 ± 16.10 | 2.1 ± 16.70 |
| Week 16 | 0.1 ± 17.77 | -0.3 ± 16.60 |
| Week 18 | 2.4 ± 16.93 | -0.0 ± 17.67 |
| Week 20 | 0.9 ± 16.01 | 0.5 ± 18.25 |
| Week 22 | 2.8 ± 21.11 | 4.0 ± 20.47 |
| Week 24 | 1.9 ± 22.60 | 0.6 ± 19.67 |
| Week 26 | -0.1 ± 21.44 | 1.2 ± 18.36 |
| Week 28 | -1.9 ± 21.02 | 2.7 ± 17.79 |
| Week 30 | 1.1 ± 20.83 | -0.3 ± 19.04 |
| Week 32 | 4.4 ± 15.08 | 0.2 ± 18.17 |
| Week 34 | 1.4 ± 18.01 | 1.7 ± 17.97 |
| Week 36 | -0.6 ± 19.18 | 0.5 ± 16.69 |
| Week 38 | 1.4 ± 18.15 | -2.2 ± 19.65 |
| Week 40 | 1.7 ± 22.20 | 0.2 ± 21.80 |
| Week 42 | -1.3 ± 21.48 | 1.8 ± 20.19 |
| Week 44 | 0.6 ± 25.33 | -1.4 ± 17.46 |
| Week 46 | 0.4 ± 23.89 | 4.0 ± 19.00 |
| Week 48 | -1.2 ± 25.03 | 0.2 ± 18.16 |
| Week 50 | 0.7 ± 21.26 | -1.9 ± 12.55 |
| Week 52 | -0.8 ± 23.28 | 1.1 ± 17.81 |
Change from baseline in Quality of Life-Bronchiectasis (QoL-B) scales (excluding QoL-B-RSS) over the double-blind treatment period: Emotional Functioning Scale. QoL-B Emotional Functioning Scale scores range from 0 to 100, with higher scores indicative of better health-related quality of life.
| score on a scale | Benralizumab 30 mg | Placebo |
|---|---|---|
| Week 2 | 0.2 ± 13.63 | 2.0 ± 17.43 |
| Week 4 | -0.7 ± 14.07 | 1.4 ± 14.42 |
| Week 6 | 3.5 ± 17.99 | 4.2 ± 14.98 |
| Week 8 | -1.2 ± 16.84 | 1.4 ± 17.77 |
| Week 10 | 0.2 ± 16.43 | -1.0 ± 16.58 |
| Week 12 | 2.8 ± 17.30 | 1.6 ± 21.38 |
| Week 14 | 4.7 ± 14.31 | 1.8 ± 20.79 |
| Week 16 | 2.2 ± 16.56 | 1.2 ± 22.48 |
| Week 18 | 3.2 ± 15.57 | 3.8 ± 21.68 |
| Week 20 | 3.9 ± 15.82 | 1.4 ± 22.27 |
| Week 22 | 2.8 ± 18.46 | 2.1 ± 23.09 |
| Week 24 | 2.4 ± 17.80 | 2.9 ± 19.32 |
| Week 26 | 3.0 ± 17.15 | 4.3 ± 22.00 |
| Week 28 | 0.4 ± 25.82 | 1.6 ± 24.43 |
| Week 30 | 2.7 ± 22.55 | 1.5 ± 23.79 |
| Week 32 | 4.0 ± 15.82 | 3.0 ± 22.42 |
| Week 34 | 1.4 ± 19.64 | 1.9 ± 23.23 |
| Week 36 | 1.9 ± 17.89 | 4.5 ± 22.75 |
| Week 38 | 2.6 ± 20.79 | 1.9 ± 22.64 |
| Week 40 | 1.7 ± 23.35 | 2.3 ± 22.28 |
| Week 42 | 1.1 ± 21.97 | 3.4 ± 22.67 |
| Week 44 | 1.9 ± 25.89 | 1.8 ± 18.95 |
| Week 46 | 3.9 ± 22.02 | 6.8 ± 22.77 |
| Week 48 | 5.8 ± 22.10 | 5.4 ± 22.83 |
| Week 50 | 5.5 ± 20.69 | 3.0 ± 18.14 |
| Week 52 | 6.0 ± 26.30 | 0.9 ± 24.98 |
Change from baseline in Quality of Life-Bronchiectasis (QoL-B) scales (excluding QoL-B-RSS) over the double-blind treatment period: Social Functioning Scale. QoL-B Social Functioning Scale scores range from 0 to 100, with higher scores indicative of better health-related quality of life.
| score on a scale | Benralizumab 30 mg | Placebo |
|---|---|---|
| Week 2 | 6.4 ± 17.60 | 4.5 ± 17.35 |
| Week 4 | 4.4 ± 18.62 | 6.3 ± 22.69 |
| Week 6 | 8.4 ± 21.60 | 5.8 ± 20.05 |
| Week 8 | 9.7 ± 23.10 | 9.2 ± 20.53 |
| Week 10 | 9.4 ± 19.64 | 6.0 ± 20.31 |
| Week 12 | 10.6 ± 23.32 | 5.8 ± 21.42 |
| Week 14 | 10.9 ± 23.03 | 7.7 ± 20.52 |
| Week 16 | 9.1 ± 20.73 | 6.0 ± 23.53 |
| Week 18 | 11.6 ± 21.61 | 10.3 ± 22.43 |
| Week 20 | 11.8 ± 22.59 | 8.9 ± 21.43 |
| Week 22 | 7.2 ± 20.42 | 9.5 ± 24.09 |
| Week 24 | 10.1 ± 24.90 | 10.7 ± 24.14 |
| Week 26 | 10.1 ± 22.86 | 9.9 ± 22.46 |
| Week 28 | 8.8 ± 24.67 | 8.7 ± 24.83 |
| Week 30 | 10.2 ± 26.57 | 7.7 ± 24.82 |
| Week 32 | 12.8 ± 23.84 | 8.6 ± 24.48 |
| Week 34 | 9.6 ± 27.93 | 9.3 ± 24.95 |
| Week 36 | 12.0 ± 27.06 | 8.1 ± 25.53 |
| Week 38 | 10.2 ± 27.83 | 6.5 ± 25.41 |
| Week 40 | 13.9 ± 32.35 | 8.3 ± 27.77 |
| Week 42 | 10.2 ± 29.40 | 8.6 ± 28.16 |
| Week 44 | 9.9 ± 28.68 | 1.8 ± 24.50 |
| Week 46 | 9.1 ± 27.40 | 6.6 ± 29.11 |
| Week 48 | 12.1 ± 27.11 | 3.9 ± 30.74 |
| Week 50 | 10.2 ± 23.60 | -1.7 ± 26.85 |
| Week 52 | 11.6 ± 27.91 | 2.3 ± 25.29 |
Change from baseline in Quality of Life-Bronchiectasis (QoL-B) scales (excluding QoL-B-RSS) over the double-blind treatment period: Vitality Scale. QoL-B Vitality Scale scores range from 0 to 100, with higher scores indicative of better health-related quality of life.
| score on a scale | Benralizumab 30 mg | Placebo |
|---|---|---|
| Week 2 | 3.0 ± 18.77 | -2.4 ± 13.54 |
| Week 4 | 3.1 ± 17.82 | 0.3 ± 15.21 |
| Week 6 | 4.0 ± 18.83 | -2.0 ± 13.88 |
| Week 8 | 4.9 ± 17.84 | -1.1 ± 16.26 |
| Week 10 | 6.4 ± 16.32 | -3.1 ± 18.83 |
| Week 12 | 5.8 ± 18.48 | -3.9 ± 16.24 |
| Week 14 | 8.8 ± 20.69 | -2.7 ± 18.22 |
| Week 16 | 5.2 ± 19.66 | -0.5 ± 19.71 |
| Week 18 | 5.0 ± 19.78 | -1.4 ± 18.69 |
| Week 20 | 7.1 ± 19.99 | -1.3 ± 19.28 |
| Week 22 | 5.7 ± 21.66 | -0.6 ± 21.04 |
| Week 24 | 4.1 ± 20.87 | 1.0 ± 19.67 |
| Week 26 | 6.2 ± 20.18 | -1.6 ± 20.66 |
| Week 28 | 3.9 ± 21.75 | -2.1 ± 21.57 |
| Week 30 | 4.4 ± 21.84 | -4.3 ± 22.74 |
| Week 32 | 6.1 ± 19.97 | 0.0 ± 20.49 |
| Week 34 | 1.1 ± 18.98 | -0.8 ± 20.96 |
| Week 36 | 1.0 ± 18.59 | -2.7 ± 18.72 |
| Week 38 | 4.1 ± 18.88 | -0.0 ± 19.52 |
| Week 40 | 2.6 ± 23.01 | -2.7 ± 21.97 |
| Week 42 | 3.0 ± 21.54 | -1.0 ± 24.37 |
| Week 44 | 2.9 ± 21.11 | -3.4 ± 21.24 |
| Week 46 | 5.2 ± 24.65 | 1.0 ± 20.10 |
| Week 48 | 2.0 ± 23.48 | -1.3 ± 20.97 |
| Week 50 | 7.7 ± 20.81 | 0.0 ± 18.14 |
| Week 52 | 5.3 ± 18.74 | -5.3 ± 23.53 |
Change from baseline in Quality of Life-Bronchiectasis (QoL-B) scales (excluding QoL-B-RSS) over the double-blind treatment period: Health Perceptions Scale. QoL-B Health Perceptions Scale scores range from 0 to 100, with higher scores indicative of better health-related quality of life.
| score on a scale | Benralizumab 30 mg | Placebo |
|---|---|---|
| Week 2 | 1.3 ± 12.95 | 3.3 ± 14.12 |
| Week 4 | 1.2 ± 14.87 | -0.2 ± 16.72 |
| Week 6 | 3.5 ± 16.90 | 3.7 ± 16.06 |
| Week 8 | 5.3 ± 17.23 | 4.3 ± 18.46 |
| Week 10 | 5.6 ± 16.57 | 2.1 ± 18.47 |
| Week 12 | 7.5 ± 16.69 | 3.3 ± 17.74 |
| Week 14 | 7.4 ± 16.78 | 1.4 ± 18.99 |
| Week 16 | 1.9 ± 16.25 | 2.4 ± 20.35 |
| Week 18 | 5.8 ± 16.68 | 1.7 ± 20.69 |
| Week 20 | 4.6 ± 18.21 | 3.9 ± 21.70 |
| Week 22 | 5.0 ± 16.70 | 6.3 ± 21.99 |
| Week 24 | 7.2 ± 17.18 | 5.0 ± 19.85 |
| Week 26 | 2.8 ± 16.76 | 5.0 ± 20.26 |
| Week 28 | 3.4 ± 18.81 | 2.4 ± 20.68 |
| Week 30 | 4.5 ± 18.03 | 4.3 ± 21.87 |
| Week 32 | 7.0 ± 16.37 | 2.4 ± 20.09 |
| Week 34 | 4.2 ± 17.68 | 2.9 ± 22.29 |
| Week 36 | 3.5 ± 17.84 | 2.0 ± 20.56 |
| Week 38 | 4.2 ± 16.30 | 3.0 ± 22.90 |
| Week 40 | 5.1 ± 16.95 | 1.4 ± 22.35 |
| Week 42 | 4.7 ± 18.38 | 4.4 ± 23.77 |
| Week 44 | 4.8 ± 21.03 | 1.5 ± 20.78 |
| Week 46 | 6.6 ± 22.45 | 1.8 ± 19.07 |
| Week 48 | 7.3 ± 21.32 | 3.9 ± 23.68 |
| Week 50 | 6.9 ± 20.42 | 4.7 ± 18.65 |
| Week 52 | 4.0 ± 21.53 | 0.4 ± 24.13 |
Change from baseline in Quality of Life-Bronchiectasis (QoL-B) scales (excluding QoL-B-RSS) over the double-blind treatment period: Treatment Burden Scale. QoL-B Treatment Burden Scale scores range from 0 to 100, with higher scores indicative of better health-related quality of life.
| score on a scale | Benralizumab 30 mg | Placebo |
|---|---|---|
| Week 2 | 3.6 ± 22.56 | -2.2 ± 16.75 |
| Week 4 | 3.7 ± 18.62 | -2.1 ± 13.34 |
| Week 6 | 6.0 ± 23.20 | -2.1 ± 15.72 |
| Week 8 | 4.8 ± 18.35 | -1.9 ± 14.87 |
| Week 10 | 4.0 ± 17.31 | 1.1 ± 17.83 |
| Week 12 | 0.3 ± 17.27 | -0.4 ± 12.54 |
| Week 14 | 0.6 ± 20.74 | -4.1 ± 14.73 |
| Week 16 | 4.4 ± 20.10 | -1.1 ± 16.34 |
| Week 18 | -1.9 ± 16.28 | -1.2 ± 14.92 |
| Week 20 | 4.1 ± 16.01 | 0.3 ± 15.84 |
| Week 22 | -1.3 ± 14.37 | -0.8 ± 16.82 |
| Week 24 | -1.0 ± 18.58 | -1.1 ± 14.45 |
| Week 26 | 1.9 ± 17.32 | 2.5 ± 15.37 |
| Week 28 | -5.1 ± 24.00 | 1.4 ± 15.11 |
| Week 30 | -2.0 ± 19.14 | -1.1 ± 18.39 |
| Week 32 | -2.1 ± 16.32 | -0.8 ± 15.12 |
| Week 34 | -0.4 ± 16.70 | -4.0 ± 17.95 |
| Week 36 | -0.7 ± 16.68 | -1.5 ± 16.69 |
| Week 38 | -4.2 ± 25.27 | -2.9 ± 21.04 |
| Week 40 | -2.0 ± 24.76 | -0.4 ± 16.15 |
| Week 42 | -1.5 ± 23.52 | 1.7 ± 18.78 |
| Week 44 | 2.1 ± 17.22 | 1.4 ± 21.00 |
| Week 46 | -0.0 ± 18.59 | 4.6 ± 14.62 |
| Week 48 | -0.9 ± 17.25 | 3.6 ± 19.96 |
| Week 50 | -2.0 ± 22.13 | -1.9 ± 18.77 |
| Week 52 | -1.9 ± 25.64 | 1.7 ± 14.94 |
Change from baseline in St. George's Respiratory Questionnaire (SGRQ) total score over the double-blind treatment period. SGRQ total scores range from 0 to 100. 100 represents the worst possible health status and 0 indicates the best possible health status.
| score on a scale | Benralizumab 30 mg | Placebo |
|---|---|---|
| Week 4 | -4.7 ± 14.92 | 0.6 ± 14.89 |
| Week 8 | -4.3 ± 15.99 | -2.4 ± 15.33 |
| Week 16 | -4.4 ± 15.03 | -0.1 ± 16.06 |
| Week 24 | -6.3 ± 16.21 | -3.9 ± 21.08 |
| Week 32 | -5.8 ± 15.73 | -1.6 ± 21.46 |
| Week 40 | -5.8 ± 17.63 | -1.6 ± 24.51 |
| Week 48 | -4.9 ± 18.58 | -0.0 ± 22.45 |
| Week 52 | -4.4 ± 20.37 | 4.8 ± 23.33 |
Collected over Double-Blind Treatment Period: From first dose of study drug until end of double-blind period, up to 52 weeks. Open-label Extension Period: From the end of the double-blind period (week 25 to 53) to the end of open-label extension period, up to 40 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Benra 30 mg - DB | 0/54 (0%) | 10/54 (18.5%) | 33/54 (61.1%) |
| Placebo - DB | 0/45 (0%) | 3/45 (6.7%) | 18/45 (40%) |
| Benra 30 mg - OLE | 0/38 (0%) | 5/38 (13.2%) | 9/38 (23.7%) |
| Placebo Swithed to Benra 30 mg - OLE | 0/40 (0%) | 4/40 (10%) | 9/40 (22.5%) |
| Event | Benra 30 mg - DB | Placebo - DB | Benra 30 mg - OLE | Placebo Swithed to Benra 30 mg - OLE |
|---|---|---|---|---|
| BronchiectasisRespiratory, thoracic and mediastinal disorders | 8/54 | 3/45 | 2/38 | 3/40 |
| Incarcerated inguinal herniaGastrointestinal disorders | 0/54 | 0/45 | 1/38 | 0/40 |
| Intestinal obstructionGastrointestinal disorders | 0/54 | 0/45 | 1/38 | 0/40 |
| COVID-19Infections and infestations | 0/54 | 0/45 | 1/38 | 0/40 |
| Pneumonia pseudomonalInfections and infestations | 0/54 | 0/45 | 1/38 | 0/40 |
| HypertensionVascular disorders | 0/54 | 0/45 | 0/38 | 1/40 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 1/54 | 0/45 | 0/38 | 0/40 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 1/54 | 0/45 | 0/38 | 0/40 |
| EnteritisGastrointestinal disorders | 1/54 | 0/45 | 0/38 | 0/40 |
| Haemophilus infectionInfections and infestations | 1/54 | 0/45 | 0/38 | 0/40 |
| Event | Benra 30 mg - DB | Placebo - DB | Benra 30 mg - OLE | Placebo Swithed to Benra 30 mg - OLE |
|---|---|---|---|---|
| COVID-19Infections and infestations | 18/54 | 10/45 | 3/38 | 1/40 |
| HeadacheNervous system disorders | 5/54 | 5/45 | 0/38 | 2/40 |
| NasopharyngitisInfections and infestations | 5/54 | 5/45 | 2/38 | 1/40 |
| Back painMusculoskeletal and connective tissue disorders | 4/54 | 2/45 | 0/38 | 1/40 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 4/54 | 0/45 | 0/38 | 0/40 |
| PyrexiaGeneral disorders | 1/54 | 3/45 | 0/38 | 0/40 |
| Abdominal pain upperGastrointestinal disorders | 3/54 | 0/45 | 0/38 | 0/40 |
| FatigueGeneral disorders | 3/54 | 0/45 | 0/38 | 1/40 |
| SinusitisInfections and infestations | 3/54 | 1/45 | 1/38 | 2/40 |
| Upper respiratory tract infectionInfections and infestations | 3/54 | 1/45 | 1/38 | 1/40 |
All participants who were randomized and received any Investigational Product were included in the full analysis set.
| Age, Continuous(years) | Benralizumab 30 mg | Placebo | Total |
|---|---|---|---|
| Mean | 59.2 ± 13.14 | 59.2 ± 15.49 | 59.2 ± 14.18 |
| Age, Customized(participants) | Benralizumab 30 mg | Placebo | Total |
|---|---|---|---|
| >= 18 to <= 65 years | 34 | 21 | 55 |
| > 65 years | 20 | 24 | 44 |
| Sex: Female, Male(Participants) | Benralizumab 30 mg | Placebo | Total |
|---|---|---|---|
| Female | 37 | 35 | 72 |
| Male | 17 | 10 | 27 |
| Ethnicity (NIH/OMB)(Participants) | Benralizumab 30 mg | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 4 | 7 | 11 |
| Not Hispanic or Latino | 50 | 38 | 88 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Benralizumab 30 mg | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 17 | 14 | 31 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 36 | 31 | 67 |
| More than one race | 1 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Jul 2021 to primary completion in Apr 2024, 32 months.
Results were first posted in Jul 2025, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Benralizumab